Regulations decried by industry weighed against importance of EU biomedical talent
Experts are divided on whether pharmaceutical companies will cut research and innovation investment in the EU and US over regulatory concerns.
Pharma giants warn that investment could shift due to new laws such as an EU plan to link regulatory protections for new treatments to the speed of their rollout. But Elizabeth Kuiper, an associate director at the European Policy Centre think tank, believes investment flight will be stemmed by the need for talented researchers.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.